Intercept Pharmaceuticals (NAS:ICPT) Total Current Liabilities

: $207.1 Mil (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Intercept Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2023 was $207.1

Intercept Pharmaceuticals Total Current Liabilities Historical Data

The historical data trend for Intercept Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22

Total Current Liabilities
114.21 162.01 179.08 168.16 230.08

Intercept Pharmaceuticals Quarterly Data

Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23

Total Current Liabilities 151.04 151.43 221.58 230.08 207.12

Intercept Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Intercept Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 94.244 + 109.569

+ Other Current Liabilities + Current Deferred Liabilities

= 26.264 + 0

= 230.1

Intercept Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 82.581 + 109.688

+ Other Current Liabilities + Current Deferred Liabilities

= 14.848 + 0

= 207.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Intercept Pharmaceuticals Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Total Current Liabilities

Comparable Companies

NAS:TNGX NAS:IMGO NAS:SGMO NAS:INBX NAS:FHTX NAS:CRBU NAS:SEER NAS:HUMA NAS:IPSC NAS:ANAB OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087

M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450

Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015

Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001

Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001

Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713

Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950

Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950

Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123

Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021

Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011

Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707

Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037

Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001

Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451

Intercept Pharmaceuticals (NAS:ICPT) Headlines

From GuruFocus

Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
By Stock market mentor 01-05-2023

Intercept Provides Update on NASH Regulatory Timeline
By GuruFocusNews 06-26-2022

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting� 2022
By Value_Insider 10-31-2022

Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
By PurpleRose 07-13-2022

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting� 2022
By Value_Insider 11-06-2022

Intercept Announces PBC Data Presentations at The International Liver Congress� 2022
By GuruFocusNews 06-21-2022

Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
By PurpleRose 07-27-2022

Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva� for PBC Outside the U.S.
By PurpleRose 07-11-2022

Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
By PurpleRose 08-19-2022

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting� 2022
By GlobeNewswire 11-06-2022

Other Sources

Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
By Yahoo Finance 2022-12-23

Needham Sticks to Their Buy Rating for Intercept Pharma (ICPT)
By tipranks.com 2023-01-19

Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
By Yahoo Finance 2023-01-04

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
By Zacks 2023-01-13

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting� 2022
By Yahoo Finance 2022-10-31

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
By Yahoo Finance 2023-01-13

Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested three years ago
By Yahoo Finance 2022-10-30

Why Intercept Pharmaceuticals Stock Is Soaring Today
By Yahoo Finance 2022-11-01

Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
By Yahoo Finance 2023-01-05

Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options
By Yahoo Finance 2022-10-12

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
By Yahoo Finance 2022-12-20

Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
By Yahoo Finance 2022-10-26

JMP Securities Keeps Their Hold Rating on Intercept Pharma (ICPT)
By tipranks.com 2023-01-19

FDA Accepts Intercept�s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
By Yahoo Finance 2023-01-19

Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?
By Yahoo Finance 2023-01-20

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Current Liabilities																151.04	151.43	221.58	230.08	207.12

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	94.244	+	109.569
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	26.264	+	0
	=	230.1

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451